Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth E Thummel

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Biochemical Pharmacology|May 8, 2012
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cellsXi Emily Zheng, Zhican Wang, Michael Z Liao, et al.
Journal of Personalized Medicine|February 2, 2018
P450 Pharmacogenetics in Indigenous North American PopulationsLindsay M Henderson, Katrina G Claw, Erica L Woodahl, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 6, 2016
Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic FactorsJulie-Anne Tanner, Bhagwat Prasad, Katrina G Claw, et al.
Cancer Chemotherapy and Pharmacology|January 13, 2006
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecanAnshul Gupta, Yang Dai, R Robert Vethanayagam, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 2020
Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition ConsiderationsRakshit S Tanna, Dan-Dan Tian, Nadja B Cech, et al.
ALTEX|July 13, 2018
Reevaluating the role of megalin in renal vitamin D homeostasis using a human cell-derived microphysiological systemBrian D Chapron, Alenka Chapron, Brian Phillips, et al.
Hepatology (Baltimore, Md.)|July 29, 2003
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver diseaseMaurice G Emery, Jeannine M Fisher, Jenny Y Chien, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2004
Evidence of significant contribution from CYP3A5 to hepatic drug metabolismWeili Huang, Yvonne S Lin, Donavon J McConn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 2, 2010
Human liver expression of CYP2C8: gender, age, and genotype effectsSuresh Babu Naraharisetti, Yvonne S Lin, Mark J Rieder, et al.
Biochemical Pharmacology|September 29, 2004
In vitro metabolism of cyclosporine A by human kidney CYP3A5Yang Dai, Kazunori Iwanaga, Yvonne S Lin, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Biochemical Pharmacology|May 8, 2012
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cellsXi Emily Zheng, Zhican Wang, Michael Z Liao, et al.
Journal of Personalized Medicine|February 2, 2018
P450 Pharmacogenetics in Indigenous North American PopulationsLindsay M Henderson, Katrina G Claw, Erica L Woodahl, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 6, 2016
Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic FactorsJulie-Anne Tanner, Bhagwat Prasad, Katrina G Claw, et al.
Cancer Chemotherapy and Pharmacology|January 13, 2006
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecanAnshul Gupta, Yang Dai, R Robert Vethanayagam, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 2020
Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition ConsiderationsRakshit S Tanna, Dan-Dan Tian, Nadja B Cech, et al.
ALTEX|July 13, 2018
Reevaluating the role of megalin in renal vitamin D homeostasis using a human cell-derived microphysiological systemBrian D Chapron, Alenka Chapron, Brian Phillips, et al.
Hepatology (Baltimore, Md.)|July 29, 2003
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver diseaseMaurice G Emery, Jeannine M Fisher, Jenny Y Chien, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2004
Evidence of significant contribution from CYP3A5 to hepatic drug metabolismWeili Huang, Yvonne S Lin, Donavon J McConn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 2, 2010
Human liver expression of CYP2C8: gender, age, and genotype effectsSuresh Babu Naraharisetti, Yvonne S Lin, Mark J Rieder, et al.
Biochemical Pharmacology|September 29, 2004
In vitro metabolism of cyclosporine A by human kidney CYP3A5Yang Dai, Kazunori Iwanaga, Yvonne S Lin, et al.
Pageof 16